Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine + Sertraline in Depression (ACE-D)
NCT06408246Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Mar 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of guanfacine in major depressive disorder (MDD), sponsored by Stanford University. Started Mar 2026; status: recruiting.
02
Drugs
guanfacine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06408246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06408246.